AI 기반 사전 승인 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI-based prior authorization market size is expected to grow from USD 1.50 billion in 2025 to USD 1.74 billion in 2026 and is forecasted to reach USD 4.21 billion by 2031 at 19.38% CAGR over 2026-2031.

This report is Segmented by Component (Software Platform and Services), Deployment Mode (Cloud-Based and On-Premise), Application (Inpatient and Outpatient Procedures, and Others), End-User (Healthcare Payers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI-Based Prior Authorization Market Trends and Insights

Surge In Payer Demand for Friction-Free Approvals

The AI-based prior authorization market is being lifted by the scale of waste tied to manual review, because CMS placed the administrative burden of prior authorization at USD 35 billion a year across the U.S. healthcare system and linked it to delays in 92% of reported care episodes.CMS also noted that physicians spent an average of 13 hours a week on prior authorization work, which translated into 700 hours and USD 34,000 per provider each year that could otherwise support patient care. That burden is not disappearing, even when payers reduce low-value requirements, because the remaining requests are becoming more clinically dense and harder to process without automation. UnitedHealthcare stated in May 2026 that it would remove prior authorization requirements for 30% of remaining services by the end of 2026, which supports the view that simpler requests are being taken out while harder cases stay in the workflow. In the AI-based prior authorization market, that pattern shifts demand toward tools that can handle specialty drugs, oncology pathways, and rare disease documentation with fewer touches and better evidence matching rather than just higher transaction volume.

CMS Interoperability Mandates (2026-2028)

The AI-based prior authorization market is seeing its strongest near-term push from CMS-0057-F, which requires Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the Federally Facilitated Exchanges to meet faster decision timelines and build FHIR-based prior authorization APIs. The January 1, 2026 effective date for the new turnaround requirements has already changed procurement behavior, because delayed implementation now carries direct operational and reputational risk for covered entities. CMS then extended the pressure in April 2026 through proposed rule CMS-0062-P, which would bring drugs billed under both medical and pharmacy benefits into the electronic prior authorization framework and would make HL7 FHIR the HIPAA administrative standard for these transactions once finalized. The annual public reporting requirement for approval rates, denial rates, and average turnaround times adds another layer, because performance is no longer only an internal operations issue and becomes visible to regulators, providers, and competing plans. Within the AI-based prior authorization market, this combination of deadlines, standards, and transparency is pushing vendors and buyers toward faster deployment cycles and a stronger focus on automation that can hold up under audit.

Data-Sharing Liability Concerns

The AI-based prior authorization market faces a real brake from data-sharing risk, because broader API-based exchange increases the number of systems and vendors that touch protected health information during prior authorization workflows. KFF highlighted a core policy gap in 2025, noting that HIPAA applies to plans, providers, and clearinghouses, but not to every AI technology vendor that may gain access to health data through interoperable systems. KFF also found that 77% of the public was concerned about the privacy of personal health information shared with AI tools, which means adoption decisions are now shaped by trust as much as by productivity. The proposed federal framework is moving toward tighter inventory, logging, and contractual controls for AI systems that access electronic protected health information, but those requirements also raise deployment cost and slow procurement. In the AI-based prior authorization market, this restraint matters because buyers want faster automation, yet they also need stronger governance, clearer business associate structures, and a cleaner legal boundary for data use before scaling across large populations.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid EHR-Payer API Standardization (HL7 FHIR-Based)
2. Cost-Containment Pressure Amid Value-Based Care Shift
3. Payer-Provider Trust Gap in Black-Box Models

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software platform held 51.44% of revenue in 2025, giving it the leading position in the AI-based prior authorization market as large commercial payers and pharmacy benefit managers continued to favor licensed platforms that fit established utilization management teams. That lead reflected buying behavior built around scale, integration control, and the ability to configure clinical pathways inside long-standing payer operations. At the same time, services is projected to advance at a 19.67% CAGR through 2031, showing that the AI-based prior authorization market is shifting toward implementation support, workflow redesign, and governance-heavy delivery rather than software licensing alone. This pattern fits the current stage of the AI-based prior authorization industry, where compliance complexity is rising faster than many organizations can absorb through internal teams.

The services expansion is being reinforced by a practical gap in capabilities, because many mid-tier payers and administrators lack the staff needed to interpret new CMS rules, configure FHIR APIs, maintain criteria libraries, and document how automated decisions are governed. As a result, the AI-based prior authorization market size for services is rising as managed services, implementation support, model monitoring, and compliance reporting are bundled into longer recurring contracts around the core platform. GenAI copilots are adding to this effect, because organizations now need support for audit logs, de-identification controls, model testing, and business associate oversight before putting conversational or ambient tools into live clinical workflows.

Cloud-based deployment accounted for 55.76% of revenue in 2025, which made it the largest deployment model in the AI-based prior authorization market and showed that buyers are already moving beyond older on-premise utilization management stacks. Cloud is also projected to grow at a 20.17% CAGR through 2031, so the same model that leads today is also widening its position as new compliance and interoperability requirements take effect. This combination is unusual in a more mature software category, because top-share segments often slow first, yet the AI-based prior authorization market remains early enough in migration that cloud still has room to pull share from legacy environments. The deployment trend also reflects the operating needs of modern prior authorization programs, where transaction volumes shift with enrollment cycles, reporting requirements are continuous, and multi-entity connectivity cannot be handled efficiently through static local infrastructure.

On-premise deployments still matter for government buyers and integrated delivery networks with strict residency or control requirements, but even those organizations are moving toward hybrid models that separate core clinical storage from scalable inference and routing functions. In the AI-based prior authorization market, cloud architecture supports API uptime measurement, auditability, and payer-to-payer data exchange in ways that are harder to reproduce economically on premises. Waystar reinforced this direction in January 2026 when it introduced agentic AI capabilities through its AltitudeAI platform to combine clinical, financial, and administrative intelligence and generate stronger justification at submission.

Complete Report Scope:

• By Component
  • Software Platform
  • Services
• By Depolyment Mode
  • Cloud-Based
  • On-Premise
• By Application
  • Inpatient and Outpatient Procedures
  • Pharmacy and Specialty Drugs
  • Durable Medical Equipment
  • Diagnostics and Imaging Approvals
• By End-User
  • Healthcare Payers
  • Healthcare Providers
  • Third-party Administrators (TPAs)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 52.23% of revenue in 2025, which gave it the leading regional position in the AI-based prior authorization market and reflected the unusually high administrative burden of the U.S. healthcare system. The region's scale is tied to a mix of private insurance complexity, Medicare Advantage utilization controls, large provider network variation, and a regulatory calendar that turned prior authorization modernization into an urgent operating need rather than a discretionary upgrade. CMS-0057-F pushed that urgency further when the January 1, 2026 deadlines made turnaround times, denial specificity, and performance reporting active obligations for covered entities. The AI-based prior authorization market in North America is also being shaped by a second policy wave, because the April 2026 CMS-0062-P proposal would extend electronic prior authorization rules to drugs billed under both medical and pharmacy benefits and widen the universe of transactions subject to digital processing. Canada and Mexico remain smaller opportunities, but both sit within a regional environment where payers and public systems are under pressure to lower administrative drag and improve approval consistency.

Asia-Pacific is projected to grow at a 21.32% CAGR through 2031, which makes it the fastest-growing regional pocket in the AI-based prior authorization market even though it starts from a smaller base than North America. The regional growth case rests on digital health infrastructure build-out, expanding claims digitization, and the fact that several countries are now creating the policy and data conditions needed for workflow automation in reimbursement review. Japan offers one of the more structured regulatory pathways for adaptive health AI products, while India's digital health push is widening the foundation for claims-linked automation as insurance penetration grows. The AI-based prior authorization market in Asia-Pacific is therefore being defined less by legacy replacement and more by the ability to build authorization workflows on top of newer digital health rails, which gives vendors room to shape process design earlier in the adoption cycle.

Europe and the Middle East & Africa show a more mixed pattern in the AI-based prior authorization market, because institutional interest in claims and workflow automation is rising while privacy and cross-border data rules remain stricter than in the United States. Europe has structurally similar approval and referral processes in several countries, but automation remains uneven and vendors must navigate tighter consent, governance, and secondary data use expectations when building scalable models. In the Middle East, GCC health systems are investing in claims management and broader digital transformation programs, which creates a longer-cycle opening for vendors with interoperable and compliance-ready platforms. South America remains more gradual, with Brazil and Argentina shaped by distinct public and private payer structures that can slow uniform rollout but still support targeted adoption where regulatory modernization improves claims workflow readiness. The AI-based prior authorization market across these regions is therefore expanding through uneven pathways, with policy clarity and data governance carrying more weight than pure technology readiness in determining adoption speed.

1. AKASA
2. Availity
3. Cognizant
4. Cohere Health
5. Edifecs
6. eviCore healthcare
7. Flatten AI
8. IBM
9. Infinx Healthcare
10. MCG Health
11. NantHealth
12. Olive AI
13. Optum
14. PriorAuthNow
15. Rhyme
16. Surescripts
17. VisiQuate
18. Waystar
19. Xealth
20. Zelis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Surge In Payer Demand for Friction-Free Approvals
  • 4.2.2 CMS Interoperability Mandates (2026-2028)
  • 4.2.3 Rapid EHR-Payer API Standardization (HL7 FHIR-Based)
  • 4.2.4 Cost-Containment Pressure Amid Value-Based Care Shift
  • 4.2.5 Emergence of GenAI Copilots for Prior-Auth Coding
  • 4.2.6 Specialty-Drug Benefit Design Complexity
• 4.3 Market Restraints
  • 4.3.1 Data-Sharing Liability Concerns
  • 4.3.2 Limited AI Training Datasets for Rare Specialties
  • 4.3.3 Payer-Provider Trust Gap in Black-Box Models
  • 4.3.4 Fragmented State-Level Rule Variations
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Software Platform
  • 5.1.2 Services
• 5.2 By Depolyment Mode
  • 5.2.1 Cloud-Based
  • 5.2.2 On-Premise
• 5.3 By Application
  • 5.3.1 Inpatient and Outpatient Procedures
  • 5.3.2 Pharmacy and Specialty Drugs
  • 5.3.3 Durable Medical Equipment
  • 5.3.4 Diagnostics and Imaging Approvals
• 5.4 By End-User
  • 5.4.1 Healthcare Payers
  • 5.4.2 Healthcare Providers
  • 5.4.3 Third-party Administrators (TPAs)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 AKASA
  • 6.3.2 Availity
  • 6.3.3 Cognizant
  • 6.3.4 Cohere Health
  • 6.3.5 Edifecs
  • 6.3.6 eviCore healthcare
  • 6.3.7 Flatten AI
  • 6.3.8 IBM
  • 6.3.9 Infinx Healthcare
  • 6.3.10 MCG Health
  • 6.3.11 NantHealth
  • 6.3.12 Olive AI
  • 6.3.13 Optum
  • 6.3.14 PriorAuthNow
  • 6.3.15 Rhyme
  • 6.3.16 Surescripts
  • 6.3.17 VisiQuate
  • 6.3.18 Waystar
  • 6.3.19 Xealth
  • 6.3.20 Zelis

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment